Back to Search
Start Over
Amelioration of elastaseāinduced lung emphysema and reversal of pulmonary hypertension by pharmacological iNOS inhibition in mice
- Source :
- British Journal of Pharmacology. 178:152-171
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- Background and purpose Chronic obstructive pulmonary disease, encompassing chronic airway obstruction and lung emphysema, is a major worldwide health problem and a severe socio-economic burden. Evidence previously provided by our group has shown that inhibition of inducible NOS (iNOS) prevents development of mild emphysema in a mouse model of chronic tobacco smoke exposure and can even trigger lung regeneration. Moreover, we could demonstrate that pulmonary hypertension is not only abolished in cigarette smoke-exposed iNOS-/- mice but also precedes emphysema development. Possible regenerative effects of pharmacological iNOS inhibition in more severe models of emphysema not dependent on tobacco smoke, however, are hitherto unknown. Experimental approach We have established a mouse model using a single dose of porcine pancreatic elastase or saline, intratracheally instilled in C57BL/6J mice. Emphysema, as well as pulmonary hypertension development was determined by both structural and functional measurements. Key results Our data revealed that (i) emphysema is fully established after 21 days, with the same degree of emphysema after 21 and 28 days post instillation, (ii) emphysema is stable for at least 12 weeks and (iii) pulmonary hypertension is evident, in contrast to smoke models, only after emphysema development. Oral treatment with the iNOS inhibitor N(6)-(1-iminoethyl)-l-lysine (L-NIL) was started after emphysema establishment and continued for 12 weeks. This resulted in significant lung regeneration, evident in the improvement of emphysema and reversal of pulmonary hypertension. Conclusion and implications Our data indicate that iNOS is a potential new therapeutic target to treat severe emphysema and associated pulmonary hypertension. Linked articles This article is part of a themed issue on Risk factors, comorbidities, and comedications in cardioprotection. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.1/issuetoc.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Swine
Hypertension, Pulmonary
medicine.medical_treatment
Gastroenterology
Tobacco smoke
Mice
03 medical and health sciences
0302 clinical medicine
Smoke
Internal medicine
Animals
Medicine
Lung emphysema
Lung
Pancreatic elastase
Saline
Emphysema
Pharmacology
Cardioprotection
ddc:610
Pancreatic Elastase
business.industry
Elastase
respiratory system
medicine.disease
Pulmonary hypertension
respiratory tract diseases
Mice, Inbred C57BL
Disease Models, Animal
030104 developmental biology
medicine.anatomical_structure
business
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 14765381 and 00071188
- Volume :
- 178
- Database :
- OpenAIRE
- Journal :
- British Journal of Pharmacology
- Accession number :
- edsair.doi.dedup.....17d22378102d8e7da6ba9d8fc219db90
- Full Text :
- https://doi.org/10.1111/bph.15057